


Citation: Hansen DK, Khouri J, Castaneda Puglianini OA, De Braganca KC, De Wiest D, Perciavalle M, et al. Patient Preferences for Use of CAR-T Therapy as an Early-Line Treatment in Multiple Myeloma. *J Cancer Immunol.* 2026;8(3):95–100.

SUPPLEMENTAL MATERIAL

Figure S1. Relative importance of treatment attributes in selection of subsequent MM therapy for patients.



CAR-T: Chimeric Antigen Receptor T-cell; MM: Multiple Myeloma